Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy

Area of Science:

• Oncology
• Immunology
• Cancer Therapy

Background:

• Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis are standard cancer treatments.
• Many tumors exhibit resistance to PD-1/PD-L1 blockade.
• CCL2 is upregulated in cancers and linked to poor prognosis, making its signaling axis a therapeutic target.

Purpose of the Study:

• To investigate the efficacy of combining CCR2 antagonism with anti-PD-1 therapy.
• To determine if this combination overcomes resistance to anti-PD-1 monotherapy in preclinical cancer models.

Main Methods:

• Utilized multiple murine tumor and metastasis models.
• Administered CCR2 antagonism in combination with anti-PD-1 therapy.
• Assessed tumor response, CD8+ T cell recruitment and activation, and CD4+ regulatory T cell populations.

Main Results:

• Combination therapy demonstrated enhanced tumor response compared to anti-PD-1 monotherapy.
• Improved treatment response correlated with increased CD8+ T cell infiltration and activation.
• Observed a decrease in CD4+ regulatory T cells in tumors treated with the combination therapy.

Conclusions:

• CCR2 antagonism synergizes with anti-PD-1 therapy to improve anti-tumor immune responses.
• This combination strategy offers a promising approach for overcoming resistance to PD-1/PD-L1 immunotherapies.
• Preclinical data support clinical trials combining CCR2 inhibitors with PD-1/PD-L1 agents for various cancers.